These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27184224)

  • 1. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
    Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
    J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.
    Sonabend AM; Ulasov IV; Han Y; Rolle CE; Nandi S; Cao D; Tyler MA; Lesniak MS
    Cancer Gene Ther; 2009 Apr; 16(4):362-72. PubMed ID: 19011597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.
    Paupoo AA; Zhu ZB; Wang M; Rein DT; Starzinski-Powitz A; Curiel DT
    Hum Reprod; 2010 Aug; 25(8):2068-83. PubMed ID: 20573677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
    Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
    Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
    Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
    Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
    Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
    Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
    Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
    Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
    Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
    Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
    Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
    Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
    Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
    Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
    Dhar D; Toth K; Wold WS
    Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
    Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
    J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.